248 related articles for article (PubMed ID: 17704825)
21. Pharmacology of cannabinoids.
Grotenhermen F
Neuro Endocrinol Lett; 2004; 25(1-2):14-23. PubMed ID: 15159677
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic potential of cannabinoid receptor ligands: current status.
Singh J; Budhiraja S
Methods Find Exp Clin Pharmacol; 2006 Apr; 28(3):177-83. PubMed ID: 16810344
[TBL] [Abstract][Full Text] [Related]
23. Primary Macrophage Chemotaxis Induced by Cannabinoid Receptor 2 Agonists Occurs Independently of the CB2 Receptor.
Taylor L; Christou I; Kapellos TS; Buchan A; Brodermann MH; Gianella-Borradori M; Russell A; Iqbal AJ; Greaves DR
Sci Rep; 2015 Jun; 5():10682. PubMed ID: 26033291
[TBL] [Abstract][Full Text] [Related]
24. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor.
Offertáler L; Mo FM; Bátkai S; Liu J; Begg M; Razdan RK; Martin BR; Bukoski RD; Kunos G
Mol Pharmacol; 2003 Mar; 63(3):699-705. PubMed ID: 12606780
[TBL] [Abstract][Full Text] [Related]
25. The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion.
Kallendrusch S; Kremzow S; Nowicki M; Grabiec U; Winkelmann R; Benz A; Kraft R; Bechmann I; Dehghani F; Koch M
Glia; 2013 Nov; 61(11):1822-31. PubMed ID: 24038453
[TBL] [Abstract][Full Text] [Related]
26. The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55.
Yamashita A; Oka S; Tanikawa T; Hayashi Y; Nemoto-Sasaki Y; Sugiura T
Prostaglandins Other Lipid Mediat; 2013 Dec; 107():103-16. PubMed ID: 23714700
[TBL] [Abstract][Full Text] [Related]
27. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.
De Petrocellis L; Di Marzo V
J Neuroimmune Pharmacol; 2010 Mar; 5(1):103-21. PubMed ID: 19847654
[TBL] [Abstract][Full Text] [Related]
28. Cannabinoids and the skeleton: from marijuana to reversal of bone loss.
Bab I; Zimmer A; Melamed E
Ann Med; 2009; 41(8):560-7. PubMed ID: 19634029
[TBL] [Abstract][Full Text] [Related]
29. A GPR18-based signalling system regulates IOP in murine eye.
Caldwell MD; Hu SS; Viswanathan S; Bradshaw H; Kelly ME; Straiker A
Br J Pharmacol; 2013 Jun; 169(4):834-43. PubMed ID: 23461720
[TBL] [Abstract][Full Text] [Related]
30. Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids.
Anavi-Goffer S; Baillie G; Irving AJ; Gertsch J; Greig IR; Pertwee RG; Ross RA
J Biol Chem; 2012 Jan; 287(1):91-104. PubMed ID: 22027819
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological profiling of the hemodynamic effects of cannabinoid ligands: a combined in vitro and in vivo approach.
Walsh SK; Hepburn CY; Keown O; Åstrand A; Lindblom A; Ryberg E; Hjorth S; Leslie SJ; Greasley PJ; Wainwright CL
Pharmacol Res Perspect; 2015 Jun; 3(3):e00143. PubMed ID: 26236485
[TBL] [Abstract][Full Text] [Related]
32. The pharmacology of cannabinoid receptors and their ligands: an overview.
Pertwee RG
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099
[TBL] [Abstract][Full Text] [Related]
33. Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro.
Harvey BS; Ohlsson KS; Mååg JL; Musgrave IF; Smid SD
Neurotoxicology; 2012 Jan; 33(1):138-46. PubMed ID: 22233683
[TBL] [Abstract][Full Text] [Related]
34. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.
Sagredo O; Ramos JA; Decio A; Mechoulam R; Fernández-Ruiz J
Eur J Neurosci; 2007 Aug; 26(4):843-51. PubMed ID: 17672854
[TBL] [Abstract][Full Text] [Related]
35. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
36. Basic neuroanatomy and neuropharmacology of cannabinoids.
Breivogel CS; Sim-Selley LJ
Int Rev Psychiatry; 2009 Apr; 21(2):113-21. PubMed ID: 19367505
[TBL] [Abstract][Full Text] [Related]
37. Evidence for the putative cannabinoid receptor (GPR55)-mediated inhibitory effects on intestinal contractility in mice.
Ross GR; Lichtman A; Dewey WL; Akbarali HI
Pharmacology; 2012; 90(1-2):55-65. PubMed ID: 22759743
[TBL] [Abstract][Full Text] [Related]
38. Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways.
Sterin-Borda L; Del Zar CF; Borda E
Biochem Pharmacol; 2005 Jun; 69(12):1705-13. PubMed ID: 15885656
[TBL] [Abstract][Full Text] [Related]
39. The endogenous cardiac cannabinoid system: a new protective mechanism against myocardial ischemia.
Lamontagne D; Lépicier P; Lagneux C; Bouchard JF
Arch Mal Coeur Vaiss; 2006 Mar; 99(3):242-6. PubMed ID: 16618028
[TBL] [Abstract][Full Text] [Related]
40. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.
Kapur A; Zhao P; Sharir H; Bai Y; Caron MG; Barak LS; Abood ME
J Biol Chem; 2009 Oct; 284(43):29817-27. PubMed ID: 19723626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
